You are here

Article Text

Article menu

Download PDFPDF

XML
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
CASE REPORT
87-year-old woman with improved pulmonary function following accidental long-term inhalation therapy with dabigatran
  1. Volker Pönitz,
  2. Karl Jakob Evensen
  1. Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
  1. Correspondence to Dr Volker Pönitz, povo{at}sus.no

Summary

Accidental long-term dabigatran etexilate inhalation was associated with subtherapeutic dabigatran serum concentrations in an elderly female patient with restrictive lung disease. A significant improvement in her pulmonary function was noted without other therapy directed towards her bronchopulmonary disease.

  • cardiovascular system
  • unwanted effects / adverse reactions
  • interstitial lung disease
  • arrhythmias

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bcr-2018-225566

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors VP and KJE have contributed to the data collection, data interpretation and manuscript writing of the current case report.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests VP has received honorary fees from Boehringer ingelheim, Pfitzer, BMS.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.